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Resistance to various anti-neoplastic agents is a com-
mon observation in clinical management of melanoma.
The biologic mechanisms conferring these di¡erent
drug-resistant phenotypes, including resistance against
the commonly used anti-cancer drug cisplatin, are
unclear. In order to elucidate the role of the mem-
brane adenosine triphosphate binding cassette-transpor-
ter cMOAT (canalicular multispeci¢c anion transporter)
(MRP2/ABCC2) in cisplatin resistance of melanoma,
the expression of this protein was analyzed in the plati-
num drug-resistant cell line MeWo CIS 1. Cisplatin-
resistant melanoma cells showed a distinct over-
expression of cMOATon mRNA and protein level. This
observation was accompanied by a reduced formation
of platinum-induced intrastrand cross-links in the nu-
clear DNA measured by an immunocytologic assay.
This decrease in DNA platination was accompanied by
an accelerated re-entry into the cell cycle after the typi-
cal cisplatin-induced G2 arrest, and a resistance to un-
dergo apoptosis. Kinetics of formation and elimination
of platinum-DNA adducts suggest that the DNA repair
capacity for Pt-d(GpG) adducts was not elevated in pla-
tinum drug-resistant melanoma cells. The decrease in
platinum-DNA adduct formation in cisplatin-resistant
melanoma cells was rather a re£ection of the protecting
activity of the transporter cMOAT. In conclusion, the
functional inhibition of cMOAT might be a promising
strategy in the reversal of resistance to platinum-based
anti-cancer drugs in human melanoma. Key words:
ABCC2/cisplatin/cMOAT/drug resistance/melanoma/MeWo/
MRP2. J Invest Dermatol 121:172 ^176, 2003
M
elanoma showed rapidly increasing incidence
and mortality rates, and is characterized by a
high risk for metastasis. A successful curative
treatment is possible only by an opportune, ade-
quate surgical resection. The bene¢t of both ad-
juvant and palliative systemic chemotherapy is not unequivocally
established. Therapeutic regimens based on dacarbazine are the
most commonly applied strategies for the treatment of dissemi-
nated melanoma; however, only a minority of patients obtain
long-lasting response rates. Various response rates have been re-
ported for polychemotherapy treatment protocols, frequently con-
taining cisplatin [cis-dichlorodiamine-platinum (II)]. Although
cisplatin is one of the most active and widely applied anti-
neoplastic agents, partial response in melanoma is observed
only for about 10% of the patients. Chemotherapeutic strategies
are extremely ine¡ective and unsatisfactory for treating melanoma
due to the pronounced drug-resistant characteristics of this
malignancy. Data from in vitro studies suggest the presence of in-
trinsic biologic mechanisms conferring this high drug resistance
(Schadendorf et al, 1994), whereby the precise cellular mechanisms
have not been identi¢ed (Helmbach et al, 2001). Despite the un-
satisfactory response rates, anti-cancer drug-based chemotherapy
will continue to be the ¢rst line treatment of disseminated mela-
noma, although there is an urgent need for improvement. One
strategy to achieve this, is to identify the molecular mechanisms
conferring drug resistance in melanoma, and, based on this
knowledge, to develop new treatment modalities to improve re-
sponse rates in melanoma patients.
In order to investigate drug resistance in human melanoma, we
have previously established and analyzed a panel of various mela-
noma-derived cell variants exhibiting di¡erent drug resistance
pro¢les (Kern et al, 1997; Lage et al, 1999, 2000, 2001; Nessling
et al, 1999; Grottke et al, 2000; Rˇnger et al, 2000; Sinha et al,
2000; Christmann et al, 2001; Helmbach et al, 2002). One of these
cell models, MeWo CIS 1, exhibiting a cisplatin-resistant pheno-
type, was established by continuous exposure of the melanoma
cell line MeWo to cisplatin.
Although only about 1% of the intracellular cisplatin reacts
with nuclear DNA, this is presumably the critical event in cispla-
tin-mediated cytotoxicity (Gonzalez et al, 2001). The two major
adducts are Pt-d(GpG) and Pt-d(ApG) intrastrand cross-links re-
presenting about 90% of the DNA platination. The other lesions
include Pt-(dG) monoadducts, Pt-d(GpNpG) intrastrand cross-
links, and Pt(dG)2 interstrand cross-links (Fichtinger-Schepman
et al, 1985). The formation of these platinium-DNA adducts per se
may not be su⁄cient to cause cell death, whereby the exact cas-
cade of the downstream events leading to cell death is not yet
clear. It is generally accepted, however, that the formation of1Both institutes contributed equally to this study.
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platinum-DNA adducts and subsequent triggering of cellular sig-
nal transduction pathways leading to apoptosis may be the pri-
mary cytotoxic mechanism of cisplatin (Fisher, 1994).
In vitro studies demonstrated that cellular mechanisms causing
resistance to cisplatin can be associated with detoxi¢cation by
methallothioneins (Kelley et al, 1988), increased glutathione (g-
glutamylcysteinyl glycine) level as well as increased activity of
glutathione-S-transferases (Zhang et al, 1998), increased DNA re-
pair (Masuda et al, 1988), decreased activity of the DNA mismatch
repair system (Lage and Dietel, 1999), reduced apoptotic response
(Perego et al, 1996), or enhanced expression of the ABC (adeno-
sine triphosphate binding cassette)-transporter cMOAT (canalicu-
lar multispeci¢c anion transporter) (Taniguchi et al, 1996), also
designated as MRP2 orABCC2. All these studies, however, were
performed using carcinoma cells derived from various nonecto-
dermal-derived cells, but not melanoma-derived cells.
MATERIALS AND METHODS
Cell culture Establishment and cell culture conditions of the cisplatin-
resistant subline MeWo CIS 1, derived from the drug-sensitive human
melanoma cell line MeWo (Fogh et al, 1978), was described earlier (Kern
et al, 1997; Lage et al, 2001).
Cell proliferation assay Chemoresistance was tested using a
proliferation assay as described previously (Lage et al, 2001).
Northern blot Expression of the cMOAT encoding mRNA was
determined by northern blot analysis applying standard procedures
as described previously (Lage et al, 2001). A 453 bp cMOAT-
speci¢c hybridization probe was generated by reverse transcription^polymerase
chain reaction (reverse transcription^PCR) using cMOAT-speci¢c oligo-
nucleotide primers designed after alignment with published sequences
(GenBank accession number NM 000392): cMOAT-forward, 50 -GGA
ACA ATT GTA GAG AAA GGA TC-30; and cMOAT-reverse, 50 -CAC
AAA CGC AAG GAT GAT GAA GAA-30. As control for equal RNA
loading the membranes were rehybridized with a glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) cDNA probe, prepared as described
in the next subsection (‘Quantitative reverse transcription^PCR’).
Quantitative reverse transcription^PCR For quantitative reverse
transcription^PCR, a real-time reverse transcription^PCR was carried
out using a LightCycler instrument (Roche Diagnostics, Mannheim,
Germany). Oligodeoxynucleotide primers used for ampli¢cation were
cMOAT-forward and cMOAT-reverse (see above) and as control
GAPDH-forward, 50 -CAC CGT CAA GGC TGA GAA C-30; and
GAPDH-reverse, 50 -ACC ACT GAC ACG TTG GCA G-30 yielding an
expected ampli¢cation product of 556 bp speci¢c for the house keeping
gene encoding GAPDH (GenBank accession number NM 002046).
Western blot Western blot experiments were performed as described
previously (Lage and Dietel, 2002). The antibodies used were a mouse
monoclonal antibody (MoAb) directed against cMOAT (clone M2I-4;
Sanbio, Uden, the Netherlands), and as control for equivalent protein
loading, a mouse MoAb directed against actin (Chemicon, Temecula,
California; no. MAB 1501R). Protein^antibody complexes were visualized
by chemoluminescence (ECL system, Amersham Aylesbury, UK).
Cell cycle analyses by £ow cytometry For cell-cycle analysis in
exponentially growing cell cultures, melanoma cells were exposed to 5 mg
cisplatin per mL. After 24 h, 48 h, or 72 h cells were ¢xed in ice-cold 75%
ethanol and stored at ^201C. After washing cells were resuspended in PBS
containing 200 mg DNase-free RNase A per mL, 50 units per mL RNAse
T1 and 20 mg propidium iodide per mL and incubated for 30 min at 251C.
Analysis was performed on a FACScan £ow cytometer (Calibur 750;
Becton Dickinson, MountainView, California) using Cellquest software.
Detection of platinum-DNA adducts Cisplatin-induced Pt-d(GpG)
intrastrand cross-links in the nuclear DNA of single cells were visualized
and measured by an immunocytologic assay using adduct-speci¢c MoAb as
described previously (Buschfort-Papewalis et al, 2002).
RESULTS AND DISCUSSION
Human melanoma is well known for its high resistance to many
anti-neoplastic agents used for therapy. In this study, the cellular
mechanisms conferring resistance to the commonly used anti-
cancer drug cisplatin were analyzed in the cisplatin-resistant mel-
anoma cell line MeWo CIS 1. Previous studies have demonstrated
that this cisplatin-resistant phenotype was accompanied by: (1) a
de¢cient DNA mismatch repair pathway (Lage et al, 1999); (2) a
modulation of DNA repair activities (Rˇnger et al, 2000); and
(3) an apoptosis de¢ciency (Helmbach et al, 2002).The fundamen-
tal biologic principle causing the cisplatin-resistant phenotype in
MeWo CIS 1, however, remained unclear.
Earlier studies demonstrated that a cisplatin-resistant pheno-
type could be associated with the overexpression of the ABC-
transporter cMOAT. In these studies carcinoma-derived cells with
acquired cisplatin resistance (Taniguchi et al, 1996; Kool et al, 1997)
or kidney cells transfected with a cMOAT encoding cDNA (Cui
Figure1. (A) Northern blot analysis of cMOAT mRNA expression
in human melanoma cells. RNA was hybridized with a 32P-labeled
cMOAT-speci¢c cDNA. As control, the blots were probed with a cDNA
probe of GAPDH. (B) Relative cMOATmRNA expression level after nor-
malization against GAPDH expression level determined by quantitative
real time reverse transcription^PCR using a LightCycler instrument. Cis-
platin-resistant MeWo CIS 1 cells showed a 3.7-fold enhanced expression of
the cMOATmRNA. (C) Western blot analysis using a mouse MoAb M2I-4
directed against cMOAT. As control, a mouse MoAb directed against actin
was used.
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et al, 1999; Kawabe et al, 1999) were used. The conclusiveness of
these studies, however, was hampered by the lack of functional
assays. Thus, here the involvement of cMOAT in platinum resis-
tance of human melanoma was investigated.
Expression analyses revealed that cMOAT is overexpressed in
the cisplatin-resistant melanoma cell MeWo CIS 1 on the mRNA
level (Fig 1A,B) as well as on the protein level (Fig 1C). No ex-
pression of alternative drug resistance-associated ABC-transpor-
ters, such as MDR1/P-glycoprotein, MRP1, or BCRP was
found in MeWo CIS 1 (data not shown); neither on mRNA level
as measured by reverse transcription^PCR and northern blot, nor
on protein level as determined by western blot. For examination
whether the cross-resistant phenotype of MeWo CIS 1 is in accor-
dance with the typical cMOAT-speci¢c cross-resistance pattern
(Cui et al, 1999), the cytotoxicities of di¡erent anti-cancer drugs
were determined (Table I). As expected for a cMOAT-mediated
cross-resistance, the cisplatin-resistant cell variant exhibited a
high cross-resistance to carboplatin, whereas no or only a weak
cross-resistance could be observed against the remaining drugs.
Flow cytometry-based cell cycle analysis revealed a typical cis-
platin-triggered G2 arrest (Chu, 1994) in drug-sensitive melanoma
cells as well as in cisplatin-resistant melanoma cells (Fig 2). After
treatment with a low cisplatin concentration (5 mg per mL) both
cell variants were able to re-enter the cell cycle, but with a
distinct delay in MeWo cells (Fig 2A,B). Exposure to a higher
dose of cisplatin (20 mg per mL) resulted in a complete G2 arrest
in MeWo cells even after 72 h with clear signs of apoptosis (Fig
2C), whereas the resistant MeWo CIS 1 cells were able to re-enter
the cell cycle (Fig 2D). The changes in cell cycle distribution of
MeWo CIS 1 cells after high dosage cisplatin (20 mg per mL) were
comparable with the e¡ect observed in the parental MeWo cells
exposed a 4-fold lower dose of the drug, which is in complete
concordance with the relative resistance factor of 3.7 (Table I).
To elucidate whether this decreased inclination to undergo cis-
platin-induced cell cycle arrest and cell death is caused by a de-
creased platinum-DNA adduct formation, by more e⁄cient
adduct repair, or by augmented tolerance to DNA damage, the
kinetics of formation and elimination of nuclear Pt-d(GpG) in-
trastrand cross-links, the major product of cisplatin-induced
DNA adducts were measured. In the ¢rst hours after cisplatin
Figure 2. Cell cycle analyses of drug-sensitive (MeWo) and cisplatin-resistant (MeWo CIS 1) melanoma cells after propidium iodide staining
using £ow cytometry. Analyses were performed at 0 h, 24 h, 48 h, and 72 h after cisplatin treatment. (A) Exposure of MeWo to 5 mg cisplatin per mL:
t¼ 0 h, 31.4% in SþG2 phase; t¼ 24 h after cisplatin treatment, 80.0% in SþG2 phase; t¼ 48 h after cisplatin treatment, 67.2% in SþG2 phase; t¼ 72 h
after cisplatin treatment, 56.1% in SþG2 phase. (B) Exposure of MeWo CIS 1^5 mg cisplatin per mL: t¼ 0 h, 30.9% in SþG2 phase; t¼ 24 h after cisplatin
treatment, 58.3% in SþG2 phase; t¼ 48 h after cisplatin treatment, 40.5% in SþG2 phase; t¼ 72 h after cisplatin treatment, 29.6% in SþG2 phase. (C)
Exposure of MeWo to 20 mg cisplatin per mL: t¼ 0 h, 31,4% in SþG2 phase; t¼ 24 h after cisplatin treatment, 87,4% in SþG2 phase; t¼ 48 h after
cisplatin treatment, 92.2% in SþG2 phase; t¼ 72 h after cisplatin treatment, 98,7% in SþG2 phase. (D) Exposure of MeWo CIS 1^20 mg cisplatin per
mL: t¼ 0 h, 30,9% in SþG2 phase; t¼ 24 h after cisplatin treatment, 79.2% in SþG2 phase; t¼ 48 h after cisplatin treatment, 66,6% in SþG2 phase;
t¼ 72 h after cisplatin treatment, 63.7% in SþG2 phase.
Table I. Cross resistance pattern of cisplatin-resistant
melanoma cells
Cell Lines
MeWo MeWo CIS 1
Drugs IC50
1 IC50
1 - RR2  p-value3
cisplatin 5.5 20.3^3.7^o 0.001
carboplatin 55.3 158.4^2.9^o 0.001
daunoblastin 0.0121 0.0162^1.3^o 0.01
etoposide 0.1957 0.3139^1.6^o 0.05
vincristine 0.000793 0.000778^1.0^n.s.4
1IC50, inhibitory concentration (mM).
2RR, relative resistance (x-fold).
3p-value, calculated by Student’s T-test.
4n.s., no signi¢cant di¡erence.
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exposure, in both melanoma variants the detected nuclear
amounts of Pt-d(GpG) adducts corresponded to the relationship
of the ongoing formation of platinum-DNA intrastrand cross-
links and the initiating adduct elimination by activated cellular
DNA repair (Fig 3). After a time period of 8 h, the peak of nu-
clear platinum-DNA adduct content was reached and then
amounts of adducts started to drop, ¢rst caused predominantly
by prevailing DNA repair and later supported by ‘‘adduct dilu-
tion’’due to ongoing cell proliferation.
At each time point after cisplatin exposure, the nuclear levels of
platinum-DNA adducts were lower in drug-resistant cells com-
pared with the cisplatin-sensitive cell line (Fig 3). MeWo CIS 1
cells did not show a faster or more e⁄cient removal of Pt-
d(GpG) cross-links in comparison with the parental MeWo cell
line, indicating that in both cell variants similar DNA repair ac-
tivities were triggered by these lesions. The fact that adduct levels
were already 2-fold lower in MeWoCIS 1 cells as early as 2 h after
cisplatin exposure (t0) clearly suggests a decreased adduct forma-
tion in these cells resulting in more convenient conditions for
proliferation, reduced cell cycle e¡ects, and less induction of
apoptosis. This situation is re£ected by the early re-entry of
MeWo CIS 1 cells into the cell cycle following G2 arrest and is
accompanied by a drug-resistant phenotype as measured in the
cell proliferation assay (Table I). Both measures, peak cross-link
formation and integrated ‘‘adducts under curve’’ values strongly
suggest a signi¢cantly reduced DNA platination by cisplatin in
MeWo CIS 1. To induce an adduct burden comparable with that
in the sensitive parental line MeWo, cisplatin-resistant cells had to
be exposed to a four times higher dose of cisplatin (20 mg per
mL) (Fig 3).
Altogether, the data imply, that the biologic mechanism lead-
ing to the decreased drug sensitivity of MeWo CIS 1 cells acts
very early after cisplatin exposure. This instantly acting resistance
mechanism might be represented by the ABC-transporter
cMOAT that can extrude platinum-based compounds from cells
directly after in£ux of the drug. Thus, cMOATwas identi¢ed as
the most decisive cellular mechanism to prevent the formation of
cisplatin-induced DNA lesions, and therewith to circumvent the
activation of signal transduction pathways leading to cell cycle ar-
rest and apoptosis in MeWo CIS 1 cells.
DNA-repair analyses from a previous study (Rˇnger et al,
2000) and the data from this study imply that neither an increase
in the activity of the nucleotide excision repair pathway nor in
the base excision repair pathway is involved in the platinum-re-
sistant phenotype of MeWo CIS 1.The decreased mismatch repair
pathway in MeWo CIS 1 (Lage et al, 1999) has most likely no in-
£uence on the elimination of platinum-DNA adducts. The mis-
match repair system rather participates in the recognition of these
adducts, and as a result, trigger pathways that end in programmed
cell death (Lage and Dietel, 1999). Lower levels of mismatch re-
pair components therefore may lead to a reduction of apoptotic
signals and therewith to an elevated survival of drug-treated tu-
mor cells.
A decreased activation of distinct apoptotic pathways has been
reported for the cisplatin-resistant melanoma cells. After treat-
ment with cisplatin (15 mg per mL) these cells showed a reduction
in caspase 9-like activity, in cytochrome c release, and in poly
(adenosine diphosphate ribose) polymerase cleavage (Helmbach
et al, 2002). In the light of the ¢ndings in this study, however,
these di¡erences are most likely due to the reduced DNA-adduct
formation in MeWo CIS 1 cells.
In summary, the data from this study taken together with pre-
viously published results indicate that the cisplatin-resistant phe-
notype of MeWo CIS 1 cells is mediated predominantly by the
decreased formation of platinum-DNA adducts due to the over-
expression of cMOAT. A 4-fold higher dose of cisplatin is neces-
sary in MeWo CIS 1 compared with MeWo cells to achieve: (1)
the same cytotoxic e¡ects; (2) a similar degree of cell cycle distur-
bance; and (3) the same burden of DNA-platination.
The data obtained in this study may be important for clinical
management of melanoma as they demonstrate that the crucial
e¡ect for the mediation of the cytotoxic e¡ects of platinum-based
anti-neoplastic agents is the formation of platinum-DNA ad-
ducts. Thus, the prevention of a decreased platinum-DNA adduct
formation in cisplatin-resistant melanoma cells is the most pro-
mising strategy to overcome cisplatin resistance. All consecutive
cellular events are merely a direct consequence of the platinum-
DNA adduct formation. Accordingly, the inhibition of the bio-
logic activity of cMOAT should be the main goal in overcoming
resistance to platinum-containing anti-cancer drugs in human mela-
noma. Moreover, cMOAT appears as an excellent candidate factor
for the diagnosis of clinical platinum resistance in melanoma.
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